Numerous studies have demonstrated that the selective estrogen receptor modulator (SERM) tamoxifen reduces tumor recurrence and lowers the chance of contralateral breast cancer when used in combination with chemotherapy (Fisher and Costantino 1999; Jordan and O’Malley 2007). Here, ESR1 is linked to breast cancer.